Dermatological research focuses on key problems in skin biology and its associated diseases, conducting basic and clinical investigations related to the prevention, diagnosis, and treatment of disorders of the skin, hair, and nails. As the largest organ in the body, skin serves as an initial barrier, dynamically interfacing with environmental insults, allergens, and pathogens. The skin is also the immunological organ system that hosts the greatest number of diseases, with estimated more than 2000 primary and systemic cutaneous diseases. This field therefore spans numerous areas, including inflammatory skin diseases, fibrotic diseases, genetic skin diseases, allergic skin disease, autoimmune disorders, neoplastic disorders, and a wide range of infectious skin diseases.
Within this spectrum, cutaneous infections constitute a significant research focus. Advances in immunology and virology have catalyzed the development of novel antiviral therapeutics, notably mRNA-based platforms demonstrating considerable promise against persistent cutaneous viral infections. Concurrently, in the domain of inflammatory dermatoses, targeted biological therapies are redefining therapeutic paradigms. Inhibitors targeting IL-4, IL-13, and IL-17 have yielded significant improvements in clinical outcomes for conditions such as atopic dermatitis and psoriasis.
Complementing therapeutic development, emerging technologies such as skin-on-a-chip platforms and 3D bioprinted skin equivalents represent transformative tools for modeling disease progression and evaluating drug responses. These bioengineered in vitro models recapitulate key structural and functional properties of human skin, thereby enabling more physiologically relevant experimentation and reducing reliance on animal models.
AcceGen supports dermatological researchers with comprehensive cellular tools. Our products include established tumor cell lines (e.g., melanoma), primary cells (e.g., keratinocytes, fibroblasts), immortalized cell lines, transfected stable cell lines, skin stem cells and induced pluripotent stem cell (iPSC)-derived skin lineages. Furthermore, tailored cellular platforms facilitate specific research applications. For instance, keratinocyte-based systems and integrated immune co-culture models provide physiologically relevant in vitro environments for investigating herpes simplex virus (HSV) pathogenesis, enabling the study of viral transmission and latency mechanisms. Additionally, our lentiviral-mediated stable transduction methodologies enable the generation of genetically modified cell lines expressing disease-relevant biomarkers or viral antigens, thereby facilitating high-throughput antiviral drug screening and mechanistic studies of viral-host interactions.
In conclusion, dermatological research represents a rapidly evolving field characterized by the integration of immunology, virology, genetics, and regenerative medicine. Deepening insights into skin pathophysiology coupled with continuous technological innovation are progressively uncovering novel therapeutic pathways. AcceGen remains a committed partner in this endeavor, offering advanced cellular platforms that empower discovery and accelerate translational innovation within dermatological science.
